Acceleron Pharma Inc. (NASDAQ:XLRN) Stake Lowered by Pictet Asset Management Ltd.

Pictet Asset Management Ltd. trimmed its position in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 629,807 shares of the biopharmaceutical company’s stock after selling 34,338 shares during the quarter. Pictet Asset Management Ltd. owned approximately 1.63% of Acceleron Pharma worth $23,504,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackRock Inc. lifted its position in Acceleron Pharma by 9.0% during the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock worth $121,719,000 after buying an additional 330,635 shares during the period. Vanguard Group Inc. lifted its position in Acceleron Pharma by 6.1% during the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock worth $61,663,000 after buying an additional 116,705 shares during the period. Westfield Capital Management Co. LP lifted its position in Acceleron Pharma by 46.6% during the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock worth $51,127,000 after buying an additional 534,440 shares during the period. Eagle Asset Management Inc. lifted its position in Acceleron Pharma by 6.6% during the second quarter. Eagle Asset Management Inc. now owns 1,256,642 shares of the biopharmaceutical company’s stock worth $38,189,000 after buying an additional 77,683 shares during the period. Finally, State Street Corp lifted its position in Acceleron Pharma by 9.4% during the second quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock worth $34,386,000 after buying an additional 97,199 shares during the period. Institutional investors own 75.85% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Acceleron Pharma Inc. (NASDAQ:XLRN) Stake Lowered by Pictet Asset Management Ltd.” was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.truebluetribune.com/2017/11/14/pictet-asset-management-ltd-has-23-50-million-stake-in-acceleron-pharma-inc-xlrn.html.

Shares of Acceleron Pharma Inc. (NASDAQ XLRN) opened at $35.02 on Tuesday. Acceleron Pharma Inc. has a 1-year low of $23.07 and a 1-year high of $41.69.

Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. During the same period last year, the firm earned ($0.55) EPS. The firm’s revenue was up .0% compared to the same quarter last year. equities analysts anticipate that Acceleron Pharma Inc. will post -2.67 EPS for the current fiscal year.

In related news, CFO Kevin F. Mclaughlin sold 16,000 shares of Acceleron Pharma stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total value of $614,560.00. Following the transaction, the chief financial officer now directly owns 50,810 shares in the company, valued at approximately $1,951,612.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Christopher Rovaldi sold 14,000 shares of Acceleron Pharma stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total value of $537,740.00. Following the completion of the transaction, the senior vice president now owns 28,232 shares in the company, valued at $1,084,391.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,513 shares of company stock worth $2,055,485. 3.90% of the stock is owned by insiders.

Several equities analysts recently weighed in on XLRN shares. Citigroup Inc. increased their target price on Acceleron Pharma to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. BidaskClub lowered Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies restated a “buy” rating and set a $40.00 price target on shares of Acceleron Pharma in a research note on Friday, July 28th. Credit Suisse Group set a $35.00 price target on Acceleron Pharma and gave the stock a “buy” rating in a research note on Saturday, August 5th. Finally, UBS AG reiterated a “buy” rating and issued a $50.00 target price (up previously from $36.00) on shares of Acceleron Pharma in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $44.88.

Acceleron Pharma Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply